Stay updated on Apremilast in Nummular Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast in Nummular Eczema Clinical Trial page.

Latest updates to the Apremilast in Nummular Eczema Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe ClinicalTrials.gov record for the apremilast study of nummular eczema is now displayed, including its study design, eligibility criteria, outcome measures, and record history.SummaryDifference50%

- Check21 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA banner announces that NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during a terminology transition. The clinical trial page continues to show a 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2; the page remains a 403 error screen.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site revision in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check63 days agoChange DetectedThe page now displays a 403 Forbidden error page with the site header and footer, indicating access is blocked rather than showing the study details.SummaryDifference19%

Stay in the know with updates to Apremilast in Nummular Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast in Nummular Eczema Clinical Trial page.